BNP Paribas Financial Markets’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-4
| Closed | -$1 | – | 4554 |
|
|
2019
Q4 | $1 | Buy |
4
+2
| +100% | – | ﹤0.01% | 4421 |
|
|
2019
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 4577 |
|
|
2019
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 4616 |
|
|
2019
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 4465 |
|
|
2018
Q4 | $1 | Hold |
2
| – | – | ﹤0.01% | 4324 |
|
|
2018
Q3 | $2 | Hold |
2
| – | – | ﹤0.01% | 4435 |
|
|
2018
Q2 | $2 | Hold |
2
| – | – | ﹤0.01% | 4414 |
|
|
2018
Q1 | $4 | Hold |
2
| – | – | ﹤0.01% | 4211 |
|
|
2017
Q4 | $2 | Hold |
2
| – | – | ﹤0.01% | 4221 |
|
|
2017
Q3 | $3 | Hold |
2
| – | – | ﹤0.01% | 4234 |
|
|
2017
Q2 | $3 | Sell |
2
-32
| -94% | -$46 | ﹤0.01% | 4254 |
|
|
2017
Q1 | $63 | Buy |
+34
| New | +$154 | ﹤0.01% | 4025 |
|
|
2016
Q4 | – | Sell |
-1,824
| Closed | -$10.2K | – | 4223 |
|
|
2016
Q3 | $10.2K | Buy |
1,824
+877
| +93% | +$5K | ﹤0.01% | 3163 |
|
|
2016
Q2 | $5.26K | Buy |
+947
| New | +$4.97K | ﹤0.01% | 3250 |
|
|
2016
Q1 | – | Sell |
-4,094
| Closed | -$24.6K | – | 3301 |
|
|
2015
Q4 | $24.6K | Buy |
4,094
+757
| +23% | +$5.14K | ﹤0.01% | 3219 |
|
|
2015
Q3 | $26.1K | Buy |
3,337
+1,937
| +138% | +$15K | ﹤0.01% | 3223 |
|
|
2015
Q2 | $8.58K | Buy |
+1,400
| New | +$10.8K | ﹤0.01% | 3365 |
|
|
2014
Q3 | – | Sell |
-308
| Closed | -$2.39K | – | 4364 |
|
|
2014
Q2 | $2.39K | Hold |
308
| – | – | ﹤0.01% | 3000 |
|
|
2014
Q1 | $2.01K | Hold |
308
| – | – | ﹤0.01% | 2661 |
|
|
2013
Q4 | $1.84K | Buy |
+308
| New | +$2.01K | ﹤0.01% | 3695 |
|
BNP Paribas Financial Markets's GNMX Position: Q1 2020 in Review
BNP Paribas Financial Markets sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 4 shares — an estimated $1 sold.
BNP Paribas Financial Markets first reported a position in GNMX in Q4 2013 and held it in 20 quarters. The position peaked at $26.1K in Q3 2015. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- BNP Paribas Financial Markets reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- BNP Paribas Financial Markets sold 4 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $1.
- BNP Paribas Financial Markets first reported a position in Aevi Genomic Medicine Inc in Q4 2013 and held it in 20 quarters.
- BNP Paribas Financial Markets's Aevi Genomic Medicine Inc position peaked at $26.1K in Q3 2015.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2020, filed 13 May 2020.